IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltration and CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Nengzhi, Shi, Jingxuan, Qin, Le, Chen, Aiming, Tang, Yuou, Yang, Hainan, Huang, Yufeng, Wu, Qingde, Li, Xufeng, He, Bingjia, Li, Tianheng, Liang, Baoxia, Zhang, Jinglin, Cao, Bihui, Liu, Manting, Feng, Yunfei, Ye, Xiaodie, Chen, Xiaopei, Wang, Lu, Tian, Yu, Li, Hao, Li, Junping, Hu, Hong, He, Jingping, Hu, Yuling, Zhi, Cheng, Tang, Zhaoyang, Gong, Yibo, Xu, Fangting, Xu, Linfeng, Fan, Weijun, Zhao, Ming, Chen, Deji, Lian, Hui, Yang, Lili, Li, Peng, Zhang, Zhenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323212/
https://www.ncbi.nlm.nih.gov/pubmed/34325726
http://dx.doi.org/10.1186/s13045-021-01128-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323212/
https://www.ncbi.nlm.nih.gov/pubmed/34325726
http://dx.doi.org/10.1186/s13045-021-01128-9

Ejemplares similares